Albert Einstein Cancer Ctr-Med - NY Bronx, Bronx 10461

Albert Einstein Cancer Ctr-Med entered the industry of Hospitals in 2010 and has grown to employ 1 to 4 people, generating an annual revenue of $500.000 to $999.999. The NAICS classifies this business under the code 6211111, which describes it as a Hospitals. For further clarification, the SIC classifies this business under the code 8062 and described it as a Hospitals. The business provides service to the B2C market.

To acquire more information, please contact Meryna Gonzalez, Manager by calling (718) 405-8505 during business hours. You can also write to the business’ Single Location at 1695 Eastchester Road, Bronx, New York NY 10461. You can also visit the company’s website at jacobipeds.org. View this business’ social media profiles on Twitter or on Facebbok .

Company: Albert Einstein Cancer Ctr-Med
Representative: Meryna Gonzalez, Manager
Place of Business: 1695 Eastchester Road, Bronx, NY 10461
Contact Number: (718) 405-8505
Website: jacobipeds.org
Type of Service: Hospitals
SIC Number: 8062
NAICS Number: 6211111
Locality: Single Location
Market Type: B2C (Business to Consumer)
Began: 2010
Income/Year: $500.000 to $999.999
Laborers: 1 to 4
Share This Company:

Albert Einstein Cancer Ctr-Med is a company operating from Bronx, New York providing professional Hospitals and relevant B2C variables. It was founded in 2010 and registered with the SIC code 8062 as Hospitals, and with the NAICS code 6211111 as Hospitals.

With a current employee count of 1 to 4, Albert Einstein Cancer Ctr-Med has gone to report making $500.000 to $999.999 per annum on its journey towards growth. This company invites you to contact its representative Meryna Gonzalez, Manager at (718) 405-8505 for related queries, or to locate its Single Location using the coordinates 40.846116,-73.844632.

The Single Location can also be found at the street address 1695 Eastchester Road in Bronx, New York 10461 and can be engaged online through the company website at jacobipeds.org, the company Twitter , and Facebook page .